JP2017527559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527559A5 JP2017527559A5 JP2017511927A JP2017511927A JP2017527559A5 JP 2017527559 A5 JP2017527559 A5 JP 2017527559A5 JP 2017511927 A JP2017511927 A JP 2017511927A JP 2017511927 A JP2017511927 A JP 2017511927A JP 2017527559 A5 JP2017527559 A5 JP 2017527559A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- isoindol
- pyridin
- imaging agent
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000012216 imaging agent Substances 0.000 claims description 56
- -1 cyano, methyl Chemical group 0.000 claims description 42
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000001475 halogen functional group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 238000012636 positron electron tomography Methods 0.000 claims description 10
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 150000002431 hydrogen Chemical group 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 208000037273 Pathologic Processes Diseases 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 4
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 230000009054 pathological process Effects 0.000 claims description 4
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 4
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 4
- RWEYYSNPCVRJSQ-UHFFFAOYSA-N C(C1=CC=CC=C1)OC=1C=C2CN(CC2=CC=1)C1=NC=NC=C1C#N Chemical compound C(C1=CC=CC=C1)OC=1C=C2CN(CC2=CC=1)C1=NC=NC=C1C#N RWEYYSNPCVRJSQ-UHFFFAOYSA-N 0.000 claims description 3
- AEFGEBPXNMNFPY-UHFFFAOYSA-N COC=1C=C2CN(CC2=CC=1)C1=C(C=NC=C1)C#N Chemical compound COC=1C=C2CN(CC2=CC=1)C1=C(C=NC=C1)C#N AEFGEBPXNMNFPY-UHFFFAOYSA-N 0.000 claims description 3
- JQYYMDQPSVKGEV-UHFFFAOYSA-N COC=1C=C2CN(CC2=CC=1)C1=NC=CC=C1C#N Chemical compound COC=1C=C2CN(CC2=CC=1)C1=NC=CC=C1C#N JQYYMDQPSVKGEV-UHFFFAOYSA-N 0.000 claims description 3
- PETGGGCVQOSNIP-UHFFFAOYSA-N COC=1C=C2CN(CC2=CC=1)C1=NC=NC=C1C#N Chemical compound COC=1C=C2CN(CC2=CC=1)C1=NC=NC=C1C#N PETGGGCVQOSNIP-UHFFFAOYSA-N 0.000 claims description 3
- HUGKALXNRWBIQE-UHFFFAOYSA-N COC=1C=CC(=NC=1)COC=1C=C2CN(C(C2=CC=1)=O)C1=CC=NC=C1 Chemical compound COC=1C=CC(=NC=1)COC=1C=C2CN(C(C2=CC=1)=O)C1=CC=NC=C1 HUGKALXNRWBIQE-UHFFFAOYSA-N 0.000 claims description 3
- REHYONXLVUWYNH-UHFFFAOYSA-N COC=1C=CC(=NC=1)COC=1C=C2CN(CC2=CC=1)C1=C(C=NC=C1)C#N Chemical compound COC=1C=CC(=NC=1)COC=1C=C2CN(CC2=CC=1)C1=C(C=NC=C1)C#N REHYONXLVUWYNH-UHFFFAOYSA-N 0.000 claims description 3
- BEDGSVZKCWBILF-UHFFFAOYSA-N COC=1C=CC(=NC=1)COC=1C=C2CN(CC2=CC=1)C1=NC=CC=C1C#N Chemical compound COC=1C=CC(=NC=1)COC=1C=C2CN(CC2=CC=1)C1=NC=CC=C1C#N BEDGSVZKCWBILF-UHFFFAOYSA-N 0.000 claims description 3
- KQORCPPKKYMCPM-UHFFFAOYSA-N COC=1C=CC(=NC=1)COC=1C=C2CN(CC2=CC=1)C1=NC=NC=C1C#N Chemical compound COC=1C=CC(=NC=1)COC=1C=C2CN(CC2=CC=1)C1=NC=NC=C1C#N KQORCPPKKYMCPM-UHFFFAOYSA-N 0.000 claims description 3
- AMAXXQKKZCHDNG-UHFFFAOYSA-N COC=1C=CC(=NC=1)COC=1C=C2CN(CC2=CC=1)C=1C=CC(N(N=1)C)=O Chemical compound COC=1C=CC(=NC=1)COC=1C=C2CN(CC2=CC=1)C=1C=CC(N(N=1)C)=O AMAXXQKKZCHDNG-UHFFFAOYSA-N 0.000 claims description 3
- QRTPOXXFPDZCES-UHFFFAOYSA-N COC=1N=CC(=NC=1)COC=1C=C2CN(CC2=CC=1)C1=CC=NC=C1 Chemical compound COC=1N=CC(=NC=1)COC=1C=C2CN(CC2=CC=1)C1=CC=NC=C1 QRTPOXXFPDZCES-UHFFFAOYSA-N 0.000 claims description 3
- VNSRTBKAWDJHOP-UHFFFAOYSA-N N1=CN=CC(=C1)COC=1C=C2CN(CC2=CC=1)C1=C(C=NC=C1)C#N Chemical compound N1=CN=CC(=C1)COC=1C=C2CN(CC2=CC=1)C1=C(C=NC=C1)C#N VNSRTBKAWDJHOP-UHFFFAOYSA-N 0.000 claims description 3
- NVXYCFAAMKMACA-UHFFFAOYSA-N N1=CN=CC(=C1)COC=1C=C2CN(CC2=CC=1)C1=NC=CC=C1C#N Chemical compound N1=CN=CC(=C1)COC=1C=C2CN(CC2=CC=1)C1=NC=CC=C1C#N NVXYCFAAMKMACA-UHFFFAOYSA-N 0.000 claims description 3
- DCRUQOOGKROGBZ-UHFFFAOYSA-N OC=1C=CC(=NC=1)COC=1C=C2CN(CC2=CC=1)C1=C(C=NC=C1)C#N Chemical compound OC=1C=CC(=NC=1)COC=1C=C2CN(CC2=CC=1)C1=C(C=NC=C1)C#N DCRUQOOGKROGBZ-UHFFFAOYSA-N 0.000 claims description 3
- JWFNVWRPBFZRLQ-UHFFFAOYSA-N OC=1C=CC(=NC=1)COC=1C=C2CN(CC2=CC=1)C1=NC=NC=C1C#N Chemical compound OC=1C=CC(=NC=1)COC=1C=C2CN(CC2=CC=1)C1=NC=NC=C1C#N JWFNVWRPBFZRLQ-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 102000014461 Ataxins Human genes 0.000 claims description 2
- 108010078286 Ataxins Proteins 0.000 claims description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 2
- 238000012879 PET imaging Methods 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000024777 Prion disease Diseases 0.000 claims description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 2
- 210000004227 basal ganglia Anatomy 0.000 claims description 2
- 238000013170 computed tomography imaging Methods 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 238000012831 peritoneal equilibrium test Methods 0.000 claims description 2
- 238000012877 positron emission topography Methods 0.000 claims description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 238000003325 tomography Methods 0.000 claims description 2
- FHMPYHRBAHQOCN-UHFFFAOYSA-N COC=1C=C2CN(C(C2=CC=1)=O)C1=CC=NC=C1 Chemical compound COC=1C=C2CN(C(C2=CC=1)=O)C1=CC=NC=C1 FHMPYHRBAHQOCN-UHFFFAOYSA-N 0.000 claims 2
- HPKKNWCMDLWNOE-UHFFFAOYSA-N COC=1C=C2CN(CC2=CC=1)C=1C=CC(N(N=1)C)=O Chemical compound COC=1C=C2CN(CC2=CC=1)C=1C=CC(N(N=1)C)=O HPKKNWCMDLWNOE-UHFFFAOYSA-N 0.000 claims 2
- VHYBOSRPUOCKTJ-UHFFFAOYSA-N OC=1C=C2CN(CC2=CC=1)C1=C(C=NC=C1)C#N Chemical group OC=1C=C2CN(CC2=CC=1)C1=C(C=NC=C1)C#N VHYBOSRPUOCKTJ-UHFFFAOYSA-N 0.000 claims 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043644P | 2014-08-29 | 2014-08-29 | |
| US62/043,644 | 2014-08-29 | ||
| PCT/US2015/047396 WO2016033436A1 (en) | 2014-08-29 | 2015-08-28 | Probes for imaging huntingtin protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020016705A Division JP6843282B2 (ja) | 2014-08-29 | 2020-02-04 | ハンチントンタンパク質のイメージング用プローブ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017527559A JP2017527559A (ja) | 2017-09-21 |
| JP2017527559A5 true JP2017527559A5 (OSRAM) | 2018-10-04 |
Family
ID=55400644
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511927A Ceased JP2017527559A (ja) | 2014-08-29 | 2015-08-28 | ハンチントンタンパク質のイメージング用プローブ |
| JP2020016705A Active JP6843282B2 (ja) | 2014-08-29 | 2020-02-04 | ハンチントンタンパク質のイメージング用プローブ |
| JP2021026146A Active JP7042940B2 (ja) | 2014-08-29 | 2021-02-22 | ハンチントンタンパク質のイメージング用プローブ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020016705A Active JP6843282B2 (ja) | 2014-08-29 | 2020-02-04 | ハンチントンタンパク質のイメージング用プローブ |
| JP2021026146A Active JP7042940B2 (ja) | 2014-08-29 | 2021-02-22 | ハンチントンタンパク質のイメージング用プローブ |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11071793B2 (OSRAM) |
| EP (1) | EP3186241B1 (OSRAM) |
| JP (3) | JP2017527559A (OSRAM) |
| KR (1) | KR102410760B1 (OSRAM) |
| CN (2) | CN107074817B (OSRAM) |
| AU (1) | AU2015308765B2 (OSRAM) |
| BR (1) | BR112017004136B1 (OSRAM) |
| CA (1) | CA2959531C (OSRAM) |
| DK (1) | DK3186241T3 (OSRAM) |
| EA (1) | EA037275B1 (OSRAM) |
| ES (1) | ES2841746T3 (OSRAM) |
| HR (1) | HRP20202032T1 (OSRAM) |
| HU (1) | HUE052892T2 (OSRAM) |
| IL (1) | IL250805B (OSRAM) |
| MX (2) | MX383202B (OSRAM) |
| PL (1) | PL3186241T3 (OSRAM) |
| PT (1) | PT3186241T (OSRAM) |
| SG (1) | SG11201701578YA (OSRAM) |
| SI (1) | SI3186241T1 (OSRAM) |
| WO (1) | WO2016033436A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3197277T3 (da) | 2014-08-29 | 2022-01-31 | Chdi Foundation Inc | Prober til billeddannelse af huntingtin-protein |
| KR102456946B1 (ko) | 2014-08-29 | 2022-10-21 | 씨에이치디아이 파운데이션, 인코포레이티드 | 헌팅틴을 단백질 영상화하기 위한 프로브 |
| CN107074817B (zh) | 2014-08-29 | 2023-12-15 | Chdi基金会股份有限公司 | 用于成像亨廷顿蛋白的探针 |
| SG11201701580XA (en) | 2014-08-29 | 2017-03-30 | Chdi Foundation Inc | Probes for imaging huntingtin protein |
| MX382156B (es) | 2015-08-28 | 2025-03-13 | Chdi Foundation Inc | Sondas para formar imagenes de proteina de huntingtina. |
| CN110225752B (zh) | 2016-09-12 | 2023-05-05 | 整体健康 | 用作gpr120调节器的单环化合物 |
| CA3041038A1 (en) | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Bicyclic compounds useful as gpr120 modulators |
| US11389438B2 (en) | 2019-02-25 | 2022-07-19 | Chdi Foundation, Inc. | Compounds for targeting mutant huntingtin protein and uses thereof |
| ES3029867T3 (en) * | 2019-12-18 | 2025-06-25 | Chdi Foundation Inc | Compounds and probes for imaging huntingtin protein |
| CN116075512A (zh) * | 2020-06-11 | 2023-05-05 | Chdi基金会股份有限公司 | 用于对亨廷顿蛋白成像的杂环化合物和显像剂 |
| CA3214756A1 (en) * | 2021-04-08 | 2022-10-13 | Longbin Liu | Isoindolinone compounds and imaging agents for imaging huntingtin protein |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5726197A (en) * | 1992-11-02 | 1998-03-10 | Syntex (U.S.A.) Inc. | Isoindolinyl derivatives |
| CN1156445C (zh) * | 1999-06-10 | 2004-07-07 | 沃尼尔·朗伯公司 | 采用二氢异吲哚衍生物抑制淀粉样蛋白聚集和使淀粉样蛋白沉积成像的方法 |
| WO2003074046A1 (en) * | 2002-03-01 | 2003-09-12 | Takeda Chemical Industries, Ltd. | Antidepressant |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7320992B2 (en) * | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| US8110681B2 (en) * | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| CA2700841A1 (en) * | 2007-09-27 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| JP5632612B2 (ja) * | 2007-12-05 | 2014-11-26 | あすか製薬株式会社 | ラクタム化合物又はその塩及びｐｐａｒ活性化剤 |
| WO2010104324A2 (ko) * | 2009-03-10 | 2010-09-16 | 한국과학기술연구원 | 베타-아밀로이드 집적체 및 피브릴에 우수한 결합 친화도를 가지는 할로겐화 이소인돌론 화합물, 및 이의 제조 방법 및 용도 |
| KR102090944B1 (ko) * | 2012-04-25 | 2020-03-19 | 라퀄리아 파마 인코포레이티드 | Ttx-s 차단제로서의 피롤로피리디논 유도체 |
| EP3055301B1 (en) * | 2013-10-07 | 2019-11-20 | Kadmon Corporation, LLC | (2-(5-isoindolin-2-yl)pyrimidin-4-yl)-amine derivatives as rho kinase inhibitors for treating autoimmune diseases |
| CN107074817B (zh) | 2014-08-29 | 2023-12-15 | Chdi基金会股份有限公司 | 用于成像亨廷顿蛋白的探针 |
| SG11201701580XA (en) | 2014-08-29 | 2017-03-30 | Chdi Foundation Inc | Probes for imaging huntingtin protein |
| KR102456946B1 (ko) | 2014-08-29 | 2022-10-21 | 씨에이치디아이 파운데이션, 인코포레이티드 | 헌팅틴을 단백질 영상화하기 위한 프로브 |
| DK3197277T3 (da) | 2014-08-29 | 2022-01-31 | Chdi Foundation Inc | Prober til billeddannelse af huntingtin-protein |
| MX382156B (es) | 2015-08-28 | 2025-03-13 | Chdi Foundation Inc | Sondas para formar imagenes de proteina de huntingtina. |
-
2015
- 2015-08-28 CN CN201580058254.1A patent/CN107074817B/zh active Active
- 2015-08-28 EA EA201790432A patent/EA037275B1/ru unknown
- 2015-08-28 CA CA2959531A patent/CA2959531C/en active Active
- 2015-08-28 JP JP2017511927A patent/JP2017527559A/ja not_active Ceased
- 2015-08-28 CN CN202311625463.2A patent/CN118005611A/zh active Pending
- 2015-08-28 HU HUE15836970A patent/HUE052892T2/hu unknown
- 2015-08-28 EP EP15836970.2A patent/EP3186241B1/en active Active
- 2015-08-28 BR BR112017004136-7A patent/BR112017004136B1/pt active IP Right Grant
- 2015-08-28 ES ES15836970T patent/ES2841746T3/es active Active
- 2015-08-28 US US15/507,214 patent/US11071793B2/en active Active
- 2015-08-28 AU AU2015308765A patent/AU2015308765B2/en active Active
- 2015-08-28 DK DK15836970.2T patent/DK3186241T3/da active
- 2015-08-28 WO PCT/US2015/047396 patent/WO2016033436A1/en not_active Ceased
- 2015-08-28 PL PL15836970T patent/PL3186241T3/pl unknown
- 2015-08-28 KR KR1020177008418A patent/KR102410760B1/ko active Active
- 2015-08-28 SG SG11201701578YA patent/SG11201701578YA/en unknown
- 2015-08-28 HR HRP20202032TT patent/HRP20202032T1/hr unknown
- 2015-08-28 MX MX2017002704A patent/MX383202B/es unknown
- 2015-08-28 SI SI201531461T patent/SI3186241T1/sl unknown
- 2015-08-28 PT PT158369702T patent/PT3186241T/pt unknown
-
2017
- 2017-02-27 IL IL250805A patent/IL250805B/en active IP Right Grant
- 2017-02-28 MX MX2021005891A patent/MX2021005891A/es unknown
-
2020
- 2020-02-04 JP JP2020016705A patent/JP6843282B2/ja active Active
-
2021
- 2021-02-22 JP JP2021026146A patent/JP7042940B2/ja active Active
- 2021-06-21 US US17/353,611 patent/US12036291B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527559A5 (OSRAM) | ||
| HRP20202032T1 (hr) | Probe za snimanje huntingtonovog proteina | |
| JP2017529340A5 (OSRAM) | ||
| JP4751957B2 (ja) | アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬 | |
| JP2017528519A5 (OSRAM) | ||
| JP2017528520A5 (OSRAM) | ||
| US7608635B2 (en) | Pyrazole compounds that modulate HSP90 activity | |
| JP2016539180A5 (OSRAM) | ||
| RU2019121871A (ru) | Новые производные фенилпропионовой кислоты и их применение | |
| US20140363830A1 (en) | Compounds that modulate hsp90 activity and methods for identifying same | |
| JP2018515555A5 (OSRAM) | ||
| JP2009541311A5 (OSRAM) | ||
| JP2014503528A5 (OSRAM) | ||
| JP2016518328A5 (OSRAM) | ||
| JP2012514007A5 (OSRAM) | ||
| NZ601794A (en) | Di - substituted pyridine derivatives as anticancers | |
| US20140094436A1 (en) | Imidazole compounds that modulate hsp90 activity | |
| US20220056052A1 (en) | Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | |
| CA2653336A1 (en) | Method for treating non-hodgkin's lymphoma | |
| US20150126499A1 (en) | Triazole Compounds that Modulate HSP90 Activity | |
| US20080027051A1 (en) | Novel Heteroaryl Substituted Benzoxazoles | |
| JP2010526800A5 (OSRAM) | ||
| JP2015531371A5 (OSRAM) | ||
| PE20170664A1 (es) | Agonistas del receptor de apelina(apj) y usos de los mismos | |
| JP2009536161A5 (OSRAM) |